A Study of Ribavirin in the Treatment of Patients With AIDS and AIDS-Related Problems

Launched by NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES (NIAID) · Aug 30, 2001

Keywords

ClinConnect Summary

RBV is a new drug capable of inhibiting the growth of the AIDS virus in the laboratory with little effect on normal human cells. In earlier tests of RBV in AIDS patients, the drug was well tolerated and safe, and this favorable result suggested that RBV should be more extensively studied in patients with AIDS and advanced AIDS related complex (ARC).

Patients are selected from three patient groups:

* Patients with AIDS, who have not taken zidovudine (AZT) within 30 days of entry into the study and who have not been discontinued from AZT because of intolerance.
* Patients with AIDS related ...

Gender

ALL

Eligibility criteria

• • Inclusion Criteria
• Concurrent Medication:
• Allowed:
• • Short-course therapy (7 days) with oral acyclovir.
• • Short-course therapy (7 days) with ketoconazole.
• • Topical medications.
• • Aerosolized pentamidine for prophylactic purposes.
• Concurrent Treatment:
• Allowed:
• • Blood transfusions for hemoglobin toxicity.
• • Patients must have two positive HIV p24 antigen tests with titers = or \> 70 picograms at least 72 hours apart and within 1 month prior to entry, the last of which must be within 2 weeks of starting therapy.
• Prior Medication:
• Allowed:
• • Zidovudine (AZT), without cessation of therapy required due to intolerance.
• • AZT therapy must be discontinued at least 30 days prior to study entry.
• • Exclusion Criteria
• Co-existing Condition:
• Patients with the following are excluded:
• • Active opportunistic infection, symptomatic visceral Kaposi's sarcoma (KS) or progression of KS within the month prior to entry into the study, neoplasms other than KS, basal cell carcinoma of the skin, or in situ carcinoma of the cervix. Significant diarrhea, defined as = or \> 3 liquid stools per day within the past week.
• Concurrent Medication:
• Excluded:
• • Ongoing systemic therapy and/or prophylaxis for an AIDS-defining opportunistic infection.
• • Antineoplastic therapy.
• • Other experimental medications.
• • Systemic chemoprophylaxis for Pneumocystis carinii pneumonia.
• • Chronic (\> 7 days) oral acyclovir therapy.
• Concurrent Treatment:
• Excluded:
• • Blood transfusions unless they are for = or \> grade 3 hemoglobin toxicity.
• Patients with the following are excluded:
• • Active opportunistic infection, symptomatic visceral Kaposi's sarcoma (KS) or progression of KS within the month prior to entry into the study, neoplasms other than KS, basal cell carcinoma of the skin, or in situ carcinoma of the cervix. Significant diarrhea, defined as = or \> 3 liquid stools per day within the past week.
• Prior Medication:
• Excluded within 30 days of study entry:
• • Antiretroviral agents including zidovudine (AZT).
• • Biologic modifiers.
• • Systemic corticosteroids.
• Prior Treatment:
• Excluded within 2 months of study entry:
• • Blood transfusion except for those who have taken zidovudine (AZT) who may not have received a transfusion within the previous month.
• • Active drug or alcohol abuse.

Trial Officials